Stock data
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX) reported revenue of US$76.20M and net income of -US$17.37M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$76.20M | — | -US$22.36M | -US$17.37M | — |
| 2024 | US$138.10M | — | US$25.00M | US$31.87M | — |
| 2023 | US$101.21M | — | -US$6.48M | -US$0.57M | — |
| 2022 | US$53.16M | — | -US$101.33M | -US$99.32M | — |
| 2021 | US$37.31M | — | -US$116.04M | -US$115.87M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$1.42M | -US$20.67M | — |
| 2026-03-31 | US$10.26M | -US$18.25M | — |
| 2025-12-31 | US$0.66M | -US$26.51M | — |
| 2025-09-30 | US$5.96M | -US$14.23M | — |
| 2025-06-30 | US$18.66M | -US$0.15M | — |
| 2025-03-31 | US$50.92M | US$23.52M | — |
| 2024-12-31 | US$38.09M | US$18.88M | — |
| 2024-09-30 | US$33.43M | US$5.74M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.